Hing C. Wong has served as our Chief Executive Officer and served on our Board, since founding HCW Biologics Inc. in April 2018. Prior to founding our company, Dr. Wong founded and served as the Chief Executive Officer of Altor BioScience Corporation, from 2002 to August 2017. After Altor was acquired in August 2017 by NantCell, Inc. (which is now ImmunityBio, Inc.), Dr. Wong served as the Chief Executive Officer of NantCell until March 2018. At Altor/NantCell, Dr. Wong led the team to invent and develop ALT-803 (now known as Anktiva) from bench through pivotal clinical trials. ALT-803 (Anktiva) was approved by USFDA as a treatment for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer in April 2024. Prior to that, Dr. Wong founded and served as Chief Executive Officer of Sunol Molecular Corporation from 1996 to 2002; the Director, Biology Skills Center of Baxter Healthcare Inc. from 1992 to 1996; and the Director of Microbial Genetics of Cetus Corporation from 1983 to 1992. Dr. Wong received his Ph.D. degree in Microbiology and Immunology at the University Massachusetts, Amherst and completed his postdoctoral training at the University of Washington.